Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
02 Feb 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/02/02/2822755/0/en/Sio-Gene-Therapies-Inc-to-File-for-Dissolution-and-Declare-an-Initial-Liquidating-Distribution-of-0-435-Per-Share.html
14 Feb 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/02/14/2607458/0/en/Sio-Gene-Therapies-Announces-Fiscal-Third-Quarter-2022-Financial-Results.html
16 Dec 2022
// Delilah Alvarado BIOPHARMADIVE
https://www.biopharmadive.com/news/sio-gene-therapy-dissolve-shut-down/638873/
14 Dec 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/12/14/2574108/0/en/Sio-Gene-Therapies-Inc-Announces-Board-Approval-of-Plan-of-Complete-Liquidation-and-Dissolution.html
10 Nov 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/11/10/2552981/0/en/Sio-Gene-Therapies-Announces-Fiscal-Second-Quarter-2022-Financial-Results.html
11 Aug 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/08/11/2496586/0/en/Sio-Gene-Therapies-Announces-Fiscal-First-Quarter-2022-Financial-Results.html
Details:
Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD.
Lead Product(s): AXO-Lenti-PD
Therapeutic Area: Neurology Brand Name: OXB-102
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Oxford Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 31, 2022
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Oxford Biomedica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD.
Brand Name : OXB-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 31, 2022
Details:
Preclinical studies in murine and a naturally-occurring feline model of GM1 gangliosidosis have supported AXO-AAV-GM1’s ability to increase β-galactosidase enzyme activity, reduce GM1 ganglioside accumulation, improve neuromuscular function, and extend survival.
Lead Product(s): AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area: Genetic Disease Brand Name: AXO-AAV-GM1
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preclinical studies in murine and a naturally-occurring feline model of GM1 gangliosidosis have supported AXO-AAV-GM1’s ability to increase β-galactosidase enzyme activity, reduce GM1 ganglioside accumulation, improve neuromuscular function, and exten...
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 21, 2021
Details:
AXO-AAV-GM1, the company’s adeno-associated viral vector (AAV)9-based gene therapy for the treatment of Type I (early infantile onset) and Type II (late infantile and juvenile onset) GM1 gangliosidosis.
Lead Product(s): AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area: Genetic Disease Brand Name: AXO-AAV-GM1
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AXO-AAV-GM1, the company’s adeno-associated viral vector (AAV)9-based gene therapy for the treatment of Type I (early infantile onset) and Type II (late infantile and juvenile onset) GM1 gangliosidosis.
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 04, 2021
Details:
Initial data from the ongoing Phase 1/2 study in five patients in the low-dose cohort showed that AXO-AAV-GM1 was generally well tolerated with a favorable safety profile and provide early indications of clinical disease stability.
Lead Product(s): AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area: Genetic Disease Brand Name: AXO-AAV-GM1
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: National Human Genome Research Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Lead Product(s) : AXO-AAV-GM1,Rituximab,Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : National Human Genome Research Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Initial data from the ongoing Phase 1/2 study in five patients in the low-dose cohort showed that AXO-AAV-GM1 was generally well tolerated with a favorable safety profile and provide early indications of clinical disease stability.
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 15, 2020
Details:
AXO-AAV-GM2 is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff diseases. The Company received a letter from the FDA indicating that it has satisfactorily addressed all issues related to the clinical hold.
Lead Product(s): AXO-AAV-GM2
Therapeutic Area: Genetic Disease Brand Name: AXO-AAV-GM2
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Lead Product(s) : AXO-AAV-GM2
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AXO-AAV-GM2 is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff diseases. The Company received a letter from the FDA indicating that it has satisfactorily addressed all issues related to the clinical hold.
Brand Name : AXO-AAV-GM2
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 09, 2020
Details:
AXO-Lenti-PD gene therapy demonstrate consistent treatment outcomes including Favorable safety and tolerability profile, with no serious adverse events attributable to gene therapy; Improvement in Hauser diary “Good ON time” and “OFF time” and other outcomes.
Lead Product(s): AXO-Lenti-PD
Therapeutic Area: Neurology Brand Name: OXB-102
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Oxford Biomedica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Oxford Biomedica
Deal Size : Not Applicable
Deal Type : Not Applicable
Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease...
Details : AXO-Lenti-PD gene therapy demonstrate consistent treatment outcomes including Favorable safety and tolerability profile, with no serious adverse events attributable to gene therapy; Improvement in Hauser diary “Good ON time” and “OFF time” and ot...
Brand Name : OXB-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 29, 2020
Details:
AXO-AAV-GM1 is the first gene therapy to enter clinical trials for GM1 gangliosidosis and the company believes that it has the potential to provide meaningful clinical benefit to both Type I and Type II patients.
Lead Product(s): AXO-AAV-GM1
Therapeutic Area: Genetic Disease Brand Name: AXO-AAV-GM1
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AXO-AAV-GM1 is the first gene therapy to enter clinical trials for GM1 gangliosidosis and the company believes that it has the potential to provide meaningful clinical benefit to both Type I and Type II patients.
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 09, 2020
Details:
AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months. EXPLORE-PD, a randomized, sham-controlled study of AXO-Lenti-PDis expected to begin dosing in 2021.
Lead Product(s): AXO-Lenti-PD
Therapeutic Area: Neurology Brand Name: OXB-102
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details : AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months. EXPLORE-PD, a randomized, sham-controlled study of AXO-Lenti-PDis expected to begin dosing in 2021.
Brand Name : OXB-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 06, 2020
Details:
Axovant will have access to manufacturing resources for Axovant’s AAV-based gene therapy programs, AXO-AAV-GM1 for GM1 gangliosidosis and AXO-AAV-GM2 for GM2 gangliosidosis with sufficient capacity to support ongoing development and eventual commercialization.
Lead Product(s): AXO-AAV-GM1
Therapeutic Area: Genetic Disease Brand Name: AXO-AAV-GM1
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Viralgen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 15, 2020
Lead Product(s) : AXO-AAV-GM1
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Recipient : Viralgen
Deal Size : Undisclosed
Deal Type : Partnership
Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership
Details : Axovant will have access to manufacturing resources for Axovant’s AAV-based gene therapy programs, AXO-AAV-GM1 for GM1 gangliosidosis and AXO-AAV-GM2 for GM2 gangliosidosis with sufficient capacity to support ongoing development and eventual commercial...
Brand Name : AXO-AAV-GM1
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 15, 2020
Details:
Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson’s Disease based on Oxford Biomedica’s LentiVector® platform.
Lead Product(s): AXO-Lenti-PD
Therapeutic Area: Neurology Brand Name: OXB-102
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Oxford Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2020
Lead Product(s) : AXO-Lenti-PD
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Oxford Biomedica
Deal Size : Undisclosed
Deal Type : Agreement
Details : Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson’s Disease based on Oxford Biomedica’s LentiV...
Brand Name : OXB-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 31, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?